Joshua Grass, Escient Pharma CEO

San Diego biotech lands $120M to launch a slate of tri­als in neu­rosen­so­ry dis­or­ders

Days af­ter adding some fi­nance, deal­mak­ing and tech­ni­cal tal­ent to the top team, Escient Phar­ma has tak­en the wraps off a $120 mil­lion round to go broad­er in the clin­ic.

New En­ter­prise As­so­ciates, Abing­worth and Forge Life Sci­ence Part­ners co-led the Se­ries C. Escient did not re­turn a re­quest for com­ment.

The San Diego biotech has been turn­ing a new page. At the be­gin­ning of the year, co-founder Alain Baron stepped down from the CEO post, mak­ing room for Joshua Grass — who brought on a trio of new ex­ecs ear­li­er this month: Aaron Mishel, CFO; David Houck, VP of chem­istry, man­u­fac­tur­ing & con­trols; and Greg Bal­ani, di­rec­tor of busi­ness de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA